Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design

Sam S. Chang

doi:10.1016/j.juro.2017.04.093

Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design

The Journal of Urology ◽

10.1016/j.juro.2017.04.093 ◽

2017 ◽

Vol 198 (2) ◽

pp. 255-255

Author(s):

Sam S. Chang

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Bacillus Calmette Guerin

Get full-text (via PubEx)

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Reply.

The Journal of Urology ◽

10.1097/ju.0000000000002238 ◽

2021 ◽

Author(s):

Patrick J. Hensley ◽

Ashish M. Kamat

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Nonmuscle Invasive Bladder Cancer

Get full-text (via PubEx)

Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design

European Urology ◽

10.1016/j.eururo.2016.02.031 ◽

2016 ◽

Vol 70 (5) ◽

pp. 778-785 ◽

Cited By ~ 18

Author(s):

Chinedu O. Mmeje ◽

Charles C. Guo ◽

Jay B. Shah ◽

Neema Navai ◽

H. Barton Grossman ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Bacillus Calmette Guerin

Get full-text (via PubEx)

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer

European Urology ◽

10.1016/j.eururo.2021.12.005 ◽

2021 ◽

Author(s):

Mathieu Roumiguié ◽

Ashish M. Kamat ◽

Trinity J. Bivalacqua ◽

Seth P. Lerner ◽

Wassim Kassouf ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Consensus Statement ◽

Clinical Trial Design ◽

Bacillus Calmette Guerin ◽

Group Consensus ◽

Muscle Invasive Bladder Cancer ◽

Cancer Group ◽

Muscle Invasive

Get full-text (via PubEx)

Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Letter.

The Journal of Urology ◽

10.1097/ju.0000000000002237 ◽

2021 ◽

Author(s):

Francesco Montorsi ◽

Marco Moschini ◽

Andrea Necchi ◽

Federico Deho ◽

Giorgio Gandaglia ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Nonmuscle Invasive Bladder Cancer

Get full-text (via PubEx)

Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

Nature Reviews Urology ◽

10.1038/s41585-021-00505-w ◽

2021 ◽

Author(s):

Elaine Chang ◽

Andrea B. Apolo ◽

Rick Bangs ◽

Stephanie Chisolm ◽

Vinay Duddalwar ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Neoadjuvant Therapy ◽

Drug Administration ◽

Trial Design ◽

Clinical Trial Design ◽

Muscle Invasive Bladder Cancer ◽

Advocacy Network ◽

Muscle Invasive ◽

Therapy Clinical Trial

Get full-text (via PubEx)

Re: Jarow JP et al.: Clinical Trial Design For the Development of New Therapies for Non–muscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop (Urology 2014;83:262-265)

Urology ◽

10.1016/j.urology.2014.03.034 ◽

2014 ◽

Vol 84 (2) ◽

pp. 494-495 ◽

Cited By ~ 2

Author(s):

John Amrhein ◽

Ashish M. Kamat ◽

Alvaro Morales

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Drug Administration ◽

Trial Design ◽

Food And Drug Administration ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Muscle Invasive Bladder Cancer ◽

Muscle Invasive ◽

American Urological Association

Get full-text (via PubEx)

Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design

The Journal of Urology ◽

10.1097/ju.0000000000001633 ◽

2021 ◽

Author(s):

Justin T. Matulay ◽

Roger Li ◽

Patrick J. Hensley ◽

Nathan A. Brooks ◽

Vikram M. Narayan ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Muscle Invasive Bladder Cancer ◽

Bcg Therapy ◽

Muscle Invasive

Get full-text (via PubEx)

Opportunities to improve clinical trial design in urothelial bladder cancer

Clinical Research and Regulatory Affairs ◽

10.3109/10601333.2015.1022282 ◽

2015 ◽

Vol 32 (2) ◽

pp. 61-69

Author(s):

Joanne W. Chiu ◽

Srikala S. Sridhar

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Urothelial Bladder Cancer ◽

Urothelial Bladder

Get full-text (via PubEx)

Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop

Urology ◽

10.1016/j.urology.2013.10.030 ◽

2014 ◽

Vol 83 (2) ◽

pp. 262-265 ◽

Cited By ~ 37

Author(s):

Jonathan P. Jarow ◽

Seth P. Lerner ◽

Paul G. Kluetz ◽

Ke Liu ◽

Rajeshwari Sridhara ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Drug Administration ◽

Trial Design ◽

Food And Drug Administration ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

New Therapies ◽

American Urological Association ◽

Nonmuscle Invasive Bladder Cancer

Get full-text (via PubEx)

Integrating radiomics into clinical trial design

The Quarterly Journal of Nuclear Medicine and Molecular Imaging ◽

10.23736/s1824-4785.19.03217-5 ◽

2019 ◽

Vol 63 (4) ◽

Cited By ~ 1

Author(s):

Jessica J. Waninger ◽

Michael D. Green ◽

Catherine Cheze Le Rest ◽

Benjamin Rosen ◽

Issam El Naqa

Keyword(s):

Clinical Trial ◽

Trial Design ◽

Clinical Trial Design

Get full-text (via PubEx)